Effect of Different Administration Routes of Dexmedetomidine Combined with Ultrasound-Guided Fascia Iliaca Block on Emergence Agitation After Hip Replacement Surgery
Recruiting now · Phase 1
Conditions studied: Dexmedetomidine, Fascia Iliaca Block
In brief
To examine the impact of various administration routes of dexmedetomidine in conjunction with ultrasound-guided fascia iliaca block (FIB) on emergence agitation (EA) during the postoperative recovery period after hip replacement surgery.
Key facts
- Study ID
- NCT06614010
- Run by
- Qianfoshan Hospital
- People needed
- 207
- Starts
- 2023-02-05
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2024-09-26
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- age between 18 and 65 years, with no restriction on gender
- diagnosis of hip joint disease necessitating hip arthroplasty
- ASA grade I-II
- no significant cardiopulmonary, hepatic, or renal dysfunction prior to the operation
- no history of psychiatric disorders or long-term use of sedative medications prior to the operation
- signing of an informed consent form to voluntarily participate in the study.
You may not qualify if…
- patients allergic to or with contraindications to ropivacaine or dexmedetomidine
- patients exhibiting symptoms of agitation or delirium prior to the procedure
- patients with severe central or peripheral nervous system disorders
- patients with coagulation disorders or receiving anticoagulant therapy
- pregnant or breastfeeding women
- patients who received other medications or treatments prior to the procedure that might affect the study results
- patients unable to cooperate with the study or intolerant to ultrasound-guided iliofascial block
Where it is running
- Qianfoshan Hospital — Jinan, Shandong, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.